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Abstract
Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disorder that begins with 
simple hepatic steatosis and progresses to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and 
even liver cancer. As the global prevalence of NAFLD rises, it is increasingly important that we 
understand its pathogenesis and develop effective therapies for this chronic disease. Forkhead box 
O (FOXO) transcription factors are key downstream regulators in the insulin/insulin-like growth 
factor 1 (IGF1) signaling pathway, and have been implicated in a range of cellular functions 
including the regulation of glucose, triglyceride, and cholesterol homeostasis. The role of FOXOs 
in the modulation of immune response and inflammation is complex, with reports of both pro- and 
anti-inflammatory effects. FOXOs are reported to protect against hepatic fibrosis by inhibiting 
proliferation and transdifferentiation of hepatic stellate cells. Mice that are deficient in hepatic 
FOXOs are more susceptible to non-alcoholic steatohepatitis than wild-type controls. In summary, 
FOXOs play a critical role in maintaining metabolic and cellular homeostasis in the liver, and 
dysregulation of FOXOs may be involved in NAFLD development.
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1. Introduction
Forkhead box O (FOXO) transcription factors belong to the O subfamily of the forkhead box 
protein family.1 There is a single FOXO gene in Caenorhabditis elegans (DAF-16) and 
Drosophila (dFOXO), and four FOXO genes (FOXO1/3/4/6) in mammals. FOXO proteins 
are highly conserved, especially the forkhead box and transactivation domains, and RAC-
alpha serine/threonine-protein kinase (AKT) conserves three major phosphorylation sites 
(Fig. 1). Mammals and other animals, such as Caenorhabditis elegans and Drosophila, share 
similar insulin/insulin-like growth factor (IGF) 1 signaling cascades (Fig. 2). Insulin/IGF1 
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activate insulin receptor/IGF1 receptor, which subsequently activate insulin receptor 
substrates through tyrosine phosphorylation. The activated insulin receptor substrates 
stimulate phosphoinositide 3-kinase, which converts Phosphatidylinositol-4,5-bisphosphate 
[PI(4,5)P2] to phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3]. This stimulates 3-
phosphoinositide-dependent protein kinase 1 and mechanistic target of rapamycin complex 
2, which activate AKT at Thr308 and Ser473, respectively.2–4 FOXOs are the immediate 
downstream effectors of AKT (Fig. 3).
FOXO transcriptional activity can be regulated by various post-translational modifications, 
though is predominantly regulated by phosphorylation and acetylation.5 AKT kinases play a 
critical role in FOXO inactivation by phosphorylating a few conserved serine/threonine sites 
of each FOXO (FOXO1-Thr24/Ser256/Ser319, FOXO3-Thr32/Ser253/Ser315, FOXO4-
Thr32/Ser197/Ser262, FOXO6-Thr26/Ser184).6 In addition to AKT, there are a number of 
other kinases that can phosphorylate FOXOs, including adenosine monophosphate (AMP)-
activated protein kinase (AMPK), c-Jun N-terminal kinase (JNK), extracellular signal-
regulated kinase (ERK), p38 mitogen-activated protein kinase, mammalian sterile 20-like 
kinase 1, and protein kinase R-like endoplasmic reticulum kinase.7 In addition to 
phosphorylation, FOXOs can be acetylated by p300/ cyclic AMP response element-binding 
protein (CBP) acetyltransferases and deacetylated by sirtuin (SIRT) 1 and histone 
deacetylase 3.8–17
FOXOs have pleiotropic functions in animal systems, with effects on cell survival, anti-
oxidative stress, autophagy, and metabolism (Fig. 4). In this short review, I will summarize 
our current understanding of liver FOXOs and their role in NAFLD development.
2. FOXOs in glucose and lipid metabolism
The interplay between FOXO transcription factors and insulin and nutrient signaling 
pathways means that FOXOs play an important role in both glucose and lipid metabolism 
(Fig. 3).18–40 The role of FOXOs in the regulation of genes that are critically involved in 
glucose, triglyceride, and cholesterol metabolism is summarized below.
2.1. FOXOs in hepatic glucose metabolism
FOXOs have been shown to play a critical role in hepatic glucose homeostasis. Knockout of 
either FoxO1 alone or FoxO1/3/4 altogether specifically in mouse liver leads to lower blood 
glucose levels under both fasting and non-fasting conditions.21,25,26,35,36,40 FoxO6 whole 
body knockout mice also exhibit lower levels of fasting and non-fasting blood glucose.18 In 
response to starvation, FOXOs transcriptionally activate the hepatic gluconeogenic program 
by inducing a number of genes including phosphoenolpyruvate carboxykinase 1, glucose-6-
phosphatase catalytic subunit, and pyruvate dehydrogenase kinase 4.24,26,35,36,38,40,41 
Meanwhile, FOXOs also inhibit glycolysis, likely through suppression of glucokinase and 
pyruvate kinase gene expression (Fig. 4).24,26,35,36,38,41 By doing so, FOXOs help maintain 
normal blood glucose levels during starvation. However, under insulin resistant or diabetic 
conditions, with the tight control of insulin signaling lacking, FOXOs continuously activate 
hepatic gluconeogenesis and thereby promote hyperglycemia.26,41
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2.2. FOXOs in hepatic triglyceride metabolism
FOXOs play a critical role in triglyceride homeostasis by regulating de novo lipogenesis, 
fatty acid oxidation, import of free fatty acids from the blood circulation, and export of 
triglyceride-rich very low density lipoproteins to the blood circulation (Fig. 4). In the 
regulation of de novo lipogenesis, FOXOs suppress the lipogenic master regulator sterol 
regulatory element binding protein (SREBP) 1 at the transcriptional level. As a result, a 
number of genes involved in fatty acid biosynthesis are also modulated by FOXOs, 
including acetyl-CoA carboxylase alpha, fatty acid synthase, adenosine triphosphate citrate 
lyase, malic enzyme 1, mitochondrial glycerol-3-phosphate acyltransferase, and stearoyl-
CoA desaturase 1.20,21,23,29,31,36–38 Moreover, FOXOs activate lipolysis and fatty acid 
oxidation genes including adipose triacylglycerol lipase, hormone-sensitive lipase, 
lipoprotein lipase, and carnitine palmitoyltransferase 1.21,31,37,38,42 Interestingly, FOXO1 
also suppresses expression of the G0/G1 switch-2 gene that encodes an inhibitor of adipose 
triacylglycerol lipase.37 FOXO1 has been shown to upregulate fatty acid transporters such as 
Leukocyte differentiation antigen CD36.43 In addition, FOXOs promote lipid droplet 
breakdown through activation of lipophagy, an autophagy process that degrades lipid 
droplets for energy production. A number of autophagy-related genes including autophagy 
related 5 (ATG5), ATG12, ATG14, beclin 1, phosphatidylinositol 3-kinase catalytic subunit 
type 3 (PIK3C3), and sestrin 3 are regulated by FOXOs. A role of autophagy in the 
promotion of lipid metabolism in the liver has been suggested by numerous studies;34,44–49 
however, the underlying mechanism remains largely unclear.
2.3. FOXOs in hepatic cholesterol metabolism
FOXOs also regulate a number of genes involved in cholesterol biosynthesis and metabolism 
(Fig. 4). SREBP-2, the master regulator of cholesterol biosynthesis, is a direct target of 
FOXOs, especially FOXO3.32 Hepatic FoxO1/3/4 triple knockouts show increased 
expression of the SREBP-2 gene.32 As expected, a number of SREBP-2 target genes 
including 3-hydroxy-3-methylglutaryl-CoA reductase and 3-hydroxy-3-methylglutaryl-CoA 
synthase 1 are also suppressed by FOXOs.21,23,32,36,38 In addition to cholesterol 
biosynthesis, FOXO1 regulates cholesterol conversion to bile acids by modulating bile acid 
biosynthetic genes including cytochrome P450 family 7 subfamily A polypeptide 1 
(CYP7A1), CYP7B1, and CYP8B1, although there are inconsistent findings with regard to 
the role of FOXO1 in the CYP7A1 gene regulation. FOXO1 also upregulates the genes 
encoding biliary cholesterol transporters—ATP binding cassette subfamily G member 5 and 
member 8.50–56
In addition, FOXOs regulate low-density lipoprotein (LDL)-cholesterol homeostasis. 
Normally, LDL-cholesterol is degraded through a LDL receptor (LDLR)-mediated clearance 
process; however, when the level of proprotein convertase subtilisin/kexin type 9 (PCSK9) is 
elevated, the interaction between PCSK9 and LDLR leads to the degradation of LDLR and 
causes an increase in LDL-cholesterol.57 Interestingly, the PCSK9 gene is suppressed by 
FOXO3 and SIRT 6. When FOXO3 or SIRT 6 is deficient in the liver, circulating LDL-
cholesterol levels are elevated.58
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3. FOXOs in non-alcoholic steatohepatitis
As FOXOs play a critical role in glucose and lipid homeostasis, it is not surprising that 
dysregulation of hepatic FOXOs may lead to metabolic disorders. Studies of FoxO gene 
knockouts and overexpression in mice have provided strong evidence regarding the role of 
FOXOs in hepatic steatosis. On a regular diet, deletion of FoxO1/3 or FoxO1/3/4 genes in 
mouse liver leads to mild or moderate hepatic steatosis, respectively.29,31,36 Overexpression 
of a constitutively active FOXO1 transgene reduces hepatic triglyceride content.37,38 When 
challenged by high-fat diets, FoxO1/3/4 liver-specific knockout mice develop very severe 
hepatic steatosis, especially on a high-fat plus cholesterol diet.29
FOXOs have been shown to modulate inflammation through regulation of a number of genes 
including interleukin 1 beta, toll-like receptor 4, C-C motif chemokine ligand 2, C-C motif 
chemokine receptor 2, and adhesion G protein-coupled receptor E1 (also named EMR1 or 
F4/80) (Fig. 4). Overexpression of constitutively active FOXO1 mutant in macrophages 
mediated by a LysM-Cre induces the expression of the C-C motif chemokine receptor 2 
gene and increases the number of proinflammatory M1-type macrophages in mouse adipose 
tissue59 (though whether similar changes occur in hepatic macrophages or Kupffer cells is 
unclear). Mice that are deficient in FoxO1/3/4 specifically in hepatocytes are susceptible to 
high-fat plus cholesterol diet-induced inflammation and liver injury.29 It has been reported 
that FOXO1 expression and activity is elevated in patients with steatohepatitis.60 More 
studies are needed to clarify the role of FOXOs in human non-alcoholic steatohepatitis.
4. FOXOs in fibrosis
Human NAFLD is a progressive liver disease that begins with simple steatosis, transitions to 
hepatic inflammation, and later develops fibrosis as extracellular matrix proteins such as 
collagen gradually accumulate in the liver. Hepatic stellate cells (HSCs) are believed to play 
a crucial role in the development of liver fibrosis.61 FOXO1 has been shown to inhibit 
proliferation and transdifferentiation of HSCs, partly through the regulation of cyclin-
dependent kinase inhibitor 1B and superoxide dismutase 2.62 After a bile duct ligation, 
FoxO1+/− mice are more predisposed to hepatic fibrosis than wild-type mice.62 Using the 
immortalized human HSC cell line LX-2, it has been shown that FOXO1 and FOXO3 are 
also involved in the tumor necrosis factor-related apoptosis-inducing ligand-mediated 
apoptosis of HSCs.63 In addition to their effect on HSCs, FOXO1/3/4 in hepatocytes play a 
protective role in diet-induced liver fibrosis. When hepatic FoxO1/3/4 genes are deleted in 
mice, expression of fibrogenic genes including type I collagen alpha 1 and tissue inhibitor of 
metalloproteinase 1 is greatly elevated after the knockout mice are challenged with either a 
high-fat or high-fat plus cholesterol diet.29
5. Conclusions
As FOXOs have been implicated in longevity in different organisms,5,64–67 their salutary 
functions in the liver, including maintaining glucose, triglyceride, and cholesterol 
homeostasis, and modulating inflammation and fibrosis, may contribute to the prolonged 
lifespan and protection against NAFLD (Fig. 5). Importantly, FOXO activity needs to be 
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controlled according to dynamic environmental cues, as over- or under-activation may lead 
to undesirable consequences. For example, under insulin resistant conditions, FOXOs are 
constitutively active, resulting in elevated hepatic glucose output and M1-type macrophage 
activation.21,30,40,59,60,68–71 Additional studies are needed to fully understand the role of 
FOXOs in normal hepatic function and NAFLD development.
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Figure 1. The insulin/insulin-like signaling pathways are evolutionally conserved
The FOXO transcription factors are regulated by the insulin/insulin-like signaling pathways 
that are well conserved in C. elegans, Drosophila, and mammals. Upon stimulation by 
insulin or insulin-like growth factors (IGFs), the insulin/IGFs receptors are activated, and 
subsequently the signaling cascade of IRS→PI3K→PDK1→AKT is activated as well. As a 
result, FOXOs are phosphorylated and inhibited by AKT.
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Figure 2. Insulin signaling and nutrient sensing pathways in hepatocytes
Major signaling cascades in the insulin and amino acid signaling pathways are outlined in 
this simplified diagram. Insulin and nutrient signaling is normally integrated to maintain 
metabolic homeostasis. Insulin plays a critical role in glucose, lipid, and protein metabolism. 
Upon insulin stimulation, the insulin signaling cascade (IR→IRS→PI3K→PDK1/
mTORC2→AKT) is activated. As a major kinase in the downstream of the insulin signaling, 
AKT controls hepatic glucose and lipid homeostasis. AKT activates glycogen synthesis by 
inhibiting GSK3 through phosphorylation. Meanwhile, AKT also inhibits the FOXO 
transcriptional activity for hepatic gluconeogenesis through phosphorylation and nuclear 
exclusion of FOXO. AKT also promotes lipid and protein synthesis through activation of 
mTORC1. In addition to insulin, amino acids also activate mTORC1 to promote protein 
synthesis and inhibit autophagy. mTORC1 stimulates lipogenesis through activation of 
SREBPs. FOXO is also modulated via deacetylation by SIRT1, an NAD+-dependent 
deacetylase. The energy sensor AMPK regulates metabolic homeostasis through activation 
of FOXO and inhibition of mTORC1.
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Figure 3. FOXOs have pleiotropic functions
Major FOXO functions are highlighted here to indicate the involvement of FOXOs in 
multiple cellular processes including cell cycle control, cell differentiation, glucose and lipid 
metabolism, energy homeostasis, autophagy, ROS detoxification, ER stress, DNA repair, and 
immune response. Numerous genes have been identified as FOXO targets. Owing to the 
limited space, only a small number of the FOXO-regulated genes for each biological process 
are listed here.
Dong Page 11





















Figure 4. A working model depicting the involvement of FOXOs in the pathogenesis of NASH
This is a very simplistic view of FOXOs in the development of NASH from the perspective 
of three major cell types in the liver – hepatocytes, Kupffer cells, and hepatic stellate cells 
(HSCs). Crosstalks between these and other cell types are not illustrated here. In 
hepatocytes, FOXOs suppress the development of steatosis by promoting lipophagy and 
fatty acid oxidation and inhibiting triglyceride and cholesterol biosynthesis. In immune cells 
including Kupffer cells and circulated macrophages, the role of FOXOs is not very clear as 
both pro- and anti-inflammation activities of FOXOs have been reported in the literature. 
Additional studies are needed to clarify the role of FOXOs in hepatic immune cells. In 
hepatic stellate cells (HSCs), FOXO1 has been shown to suppress HSC proliferation and 
transdifferentiation, thus inhibiting hepatic fibrosis.
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